ACRO BIOMEDICAL CO., LTD. (ACBM) Return on equity 2017–2022
ACRO BIOMEDICAL CO., LTD. (ACBM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-3263.2%FY2022 · since FY2017: -0.4% → -3263.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -3263.2% | -2067.4 pp |
| FY2021 | -1195.9% | -1178.7 pp |
| FY2020 | -17.1% | +29.4 pp |
| FY2019 | -46.6% | -80.3 pp |
| FY2018 | 33.8% | +34.2 pp |
| FY2017 | -0.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ACBM financial trends
ACBM RevenueACBM Net incomeACBM Net marginACBM Gross profitACBM Gross marginACBM Operating incomeACBM Operating marginACBM Operating cash flowACBM Free cash flowACBM Capital expendituresACBM Stock buybacksACBM Dividends paidACBM Total assetsACBM Total liabilitiesACBM Shareholders’ equityACBM overview →